Introduction {#s0005}
============

In recent years, although tumor tissue is still quoted as the "gold standard" for tumor genotyping, bloodstream-based genetic analyses---termed as "liquid biopsy" is emerging as an important approach [@bb0005]. For lung cancer, epidermal growth factor receptor (EGFR) mutation was regarded as the strongest predictor of effectiveness of treatment with EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib [@bb0010], [@bb0015]. Many methods have been reported for detecting *EGFR* mutation in plasma cell-free DNA (cfDNA) of lung cancer patients, including Amplification Refractory Mutation System (ARMS) [@bb0020], [@bb0025], PNA-clamp [@bb0030], denaturing high-performance liquid chromatography (DHPLC) [@bb0035], and next-generation sequencing (NGS) [@bb0040]. The sensitivity and specificity of these technologies varied significantly among different studies. Droplet digital PCR (ddPCR) was reported with the sensitivity and specificity of 81.82% and 98.44% [@bb0045], respectively. Due the high sensitivity and specificity, ddPCR was favored by many researchers for plasma EGFR mutation detecting. Recently, a novel technique called SuperARMS, which was reported with high sensitive and specific, provides a promising approach for cfDNA detection [@bb0050].

In our pilot study, we detected 79 pairs plasma samples of non-small cell lung cancer patients used ADx-ARMS and SuperARMS, resulted showed the sensitivity of SuperARMS was higher than ARMS. Few studies were performed to compare SuperARMS and ddPCR for genotyping. In this reason, we use ddPCR and SuperARMS to detect plasma *EGFR* status in a cohort of advanced NSCLC patients.

Patients and Methods {#s0010}
====================

Patients {#s0015}
--------

A total of 79 patients were enrolled in this study, which were collected from Jan 1, 2012, to Jun 1, 2013, at The First People\'s Hospital of Foshan. All patients were histologically confirmed lung adenocarcinoma (include two adenosquamous carcinoma). Sufficient tumor tissue specimens and plasma specimens were sampled. The study was approved by the ethics committee of The First People\'s Hospital of Foshan. All patients had provided written information consents before the study procedures. Patients were followed up every month by the investigators.

Sample Collection and DNA Extraction {#s0020}
------------------------------------

Tumor tissue sample and matched plasma with an interval less than 1 week was collected for each patient. All tumor tissue samples were formalin-fixed and paraffin-embedded (FFPE), and underwent pathologic evaluation to ensure the tumor content of at least 20%.

Tumor tissue DNA from FFPE was extracted by using an FFPE DNA Kit (Amoy Diagnostics Co, Xiamen, China) according to the standard protocols. Plasma was separated from 10 ml of peripheral blood from each patient before EGFR-TKI treatment. Then, cfDNA was isolated using a plasma/serum cell-free DNA kit (Amoy Diagnostics Co, Xiamen, China) according to the manufacturer's instructions.

EGFR Mutation Detection {#s0025}
-----------------------

The EGFR mutations of the extracted DNA from the tissue were assessed with the amplification refractory mutation system (ARMS) by using an EGFR mutations detection Kit (Amoy Diagnostics, Xiamen, China) according to the manufacturer's instructions. The method was reported previously [@bb0055].

Plasma DNA was analyzed by ddPCR and SuperARMS, respectively. The ddPCR was performed according to the manufacturer's instructions and this method was reported previously [@bb0045].

The SuperARMS assay (Amoy Diagnostics, Xiamen, China), which is newly designed based on ARMS with indicative detection limit of 0.2% as the kit specification claims. This kit adopts both ARMS and real-time PCR technologies to identify 41 of the most common hotspots in EGFR exons 18-21 in plasma ctDNA samples. So far, the kit is for research use only. All samples were carried out following the manufacturer's protocol. Briefly, the ADx-SuperARMS PCR was implemented in a final 80 μL reaction mixture consisting of 15 μL DNA templates as well as novel proprietary primers and probes, dNTPs, buffer, Mg2+ and Taq DNA polymerases. PCR reactions were carried out on Mx3000P PCR system using the cycling conditions as follows: 1 cycle at 95°C for 10 min for incubation, followed by 15 cycles at 95°C for 40 seconds, 64°C for 40 seconds and 72°C for 30 seconds, and then 28 cycles at 93°C for 40 seconds, 60°C for 45 seconds and 72°C for 30 seconds. The raw data were analyzed using the MxPro-Mx3000P v4.10 included with the instrument. ∆Ct was calculated as: mutant Ct value---internal control Ct value. If ∆Ct is less than the Cut-off value, the result is determined as positive. Otherwise, the result is determined as negative or beyond the limit of detection.

Statistical Analysis {#s0030}
--------------------

Statistical analyses were performed with the IBM SPSS Statistics version 20. McNemar test was used to analysis the concordance of *EGFR* mutation between matched samples. The progression-free survival (PFS) according to *EGFR* mutation status was estimated by Kaplan--Meier method and the difference in survival was compared using log-rank test. *P* \< .05 was deemed to be of statistical significance. All *P* values and 95% confidence intervals (95%CI) were two-sided.

Results {#s0035}
=======

Patients Clinical Characteristics {#s0040}
---------------------------------

A total of 79 patients were enrolled and 79 pairs of tumor tissue and plasma samples were collected. All tissue samples were tested *EGFR* mutation status by ADx-ARMS successfully. There were 51 (64.6%) patients harbor *EGFR*-activating mutations, among whom 26 were exon 21 L858R mutation and 25 were exon 19 deletion. 28 (35.4%) harbored wild-type *EGFR*. The *EGFR* mutation status in tumor tissue by ADx-ARMS was regarded as "gold standard" in the study. The clinical characteristics of patients were shown in [Table 1](#t0005){ref-type="table"}.Table 1Baseline demographic and clinical characteristics.Table 1CharacteristicsNo. of patients (%)Sex Male36 (45.6%) Female43(54.4%)Age Median59 (30-75) \<6043 (54.4%) ≧6036 (45.6%)Smoking status Never-smoker54 (68.4%) Current/ever-smoker25(31.6%)ECOG PS PS 0-172 (91.1%) PS 27 (8.9%)*EGFR* mutation in tissue Mutation+51 (64.6%) Wild-type28 (35.4%)Histology adenocarcinoma77 (97.5%) adenosquamous2 (2.5%)

*EGFR* Mutation in Plasma by SuperARMS and ddPCR {#s0045}
------------------------------------------------

All 79 plasma samples were detected *EGFR* mutation status by ddPCR and SuperARMS successfully. When tested by ddPCR, 44 of 79 (55.7%) patients were identified to be *EGFR* mutation, including three patients who were detected to be wild-type in tumor tissue, which was considered as false positive. The sensitivity, specificity, positive predictive value and negative predictive value was 80.4%, 89.4%, 93.2%, 71.4%, respectively. The concordance of *EGFR* mutations between plasma and tissue was 83.5% by ddPCR.

When using SuperARMS to detect plasma *EGFR*, 39 of 79 (49.4%) patients were demonstrated to be *EGFR* mutation. Twelve patients were *EGFR* mutation in tumor tissue but *EGFR* wild-type in plasma. The sensitivity and negative predictive value of SuperARMS was 76.5% and 70.0%, respectively. The specificity and positive predictive value were both 100%. The concordance of *EGFR* mutations between plasma and tissue was 84.8%. The result of *EGFR* mutation status by ddPCR and SuperARMS was shown in [Table 2](#t0010){ref-type="table"}.Table 2EGFR mutation status by ddPCR and SuperARMS.Table 2Plasma cfDNATumor tissueResults**SuperARMS**M+M-TotalSensitivity = 76.5% M+39039Specificity = 100% M-122840Positive predictive value = 100% Total512879Negative predictive value = 70.0%\
Concordance = 84.8%**ddPCR**M+M-TotalSensitivity = 80.4% M+41344Specificity = 89.3% M-102535Positive predictive value = 93.2% Total512879Negative predictive value = 71.4%\
Concordance = 83.5%

Compare SuperARMS with ADx-ARMS in Plasma *EGFR* Detection {#s0050}
----------------------------------------------------------

The sensitivity of ddPCR was similar with Super-ARMS in plasma *EGFR* detection (80.4% vs. 76.5%), as well as the specificity (89.3% vs 100%). The McNemar's test showed there was no significant difference (*P* = .125). And the concordance rate of *EGFR* mutation status between SuperARMS and ddPCR was 91.1% (72/79).

*EGFR* Mutation Status and Prediction of EGFR-TKI Efficacy {#s0055}
----------------------------------------------------------

There were 51 patients who received EGFR-TKI treatment. The overall objective response rate (ORR) was 56.9% (29/51) for EGFR-TKI treatment.

For plasma samples by ddPCR, the ORR was 67.6% (25/37) and 28.6% (4/14) respectively in patients with or without *EGFR* mutation, *P* = .025. Median PFS was significantly prolonged in *EGFR* mutation patients compared with *EGFR* wild-type patients (12.0months vs 5.0 months, *P* = .009) ([Figure 1](#f0005){ref-type="fig"}A).Figure 1PFS in EGFR mutation patients compared with EGFR wild-type patients.(A) Plasma samples by ddPCR. (B) Plasma samples by SuperARMS.Figure 1

For plasma samples by SurperARMS, the ORR in *EGFR* mutation or wild-type patients was 74.2% (23/31) and 30.0% (6/20), respectively, *P* = .002. *EGFR* mutation patients tended to have longer PFS than those with *EGFR* wild-type patients (12.0months vs 5.5 months, *P* = .009) ([Figure 1](#f0005){ref-type="fig"}B).

These data suggested that *EGFR* mutation status in blood detected by ddPCR and SuperARMS can be predictive of tumor response to EGFR-TKIs and survival results.

Discussion {#s0060}
==========

Nowadays, liquid biopsy represents a promising approach for noninvasive assessment of cancer gene profile. In this study, we performed a comparison of ddPCR and SuperARMS for the detection of the EGFR mutation in plasma cfDNA from NSCLC patients. All plasma samples were successfully processed for DNA extraction and genotyping. Our results suggested that both SuperARMS and ddPCR have high sensitivity and specificity for EGFR detection in plasma samples, and are good predictors of the efficacy of EGFR-TKIs.

Various methods had been reported to detect EGFR mutation in cfDNA of lung cancer patients. The ddPCR was one with high sensitivity and specificity that was widely used. Zhu et al had optimized the ddPCR assays to reach the sensitivity of 0.04%.[@bb0045] In his study, EGFR Exon19-Del mutation was detected with the sensitivity of 81.82% and the specificity of 98.44%, while EGFR L858R mutation was tested with sensitivity of 80.00% and the specificity of 95.77%, compared with the paired tumor tissues. Oxnard et al. reported the ddPCR assays for detecting EGFR with high sensitivity and 100% specificity and ddPCR was demonstrated valuable in monitoring resistance mutations which may offer broader clinical application [@bb0060]. The results were consisted with that in our study. The SuperARMS is a novel technique which was modified on the basis of ARMS by optimizing the primers designation, PCR amplification reaction-system, which makes it much more sensitive. Preciously, Li et al. used SuperARMS to test plasma *EGFR* mutation of 109 patients, results showed the sensitivity of 82% and specificity of 100%, and the concordance rate between plasma and tissue was 89.9%[@bb0050]. The results were concordant with our study, with sensitivity of 76.5% and specificity of 100%, the concordance between plasma and tissue was 84.8%. The sensitivity of ddPCR was similar with Super-ARMS (80.4% vs 76.5%), while the specificity tended to be lower (89.3% vs 100%), but there was no significant difference (*P* = .125). One great advantage of ddPCR is the quantification of DNA; SuperARMS cannot quantify but it is fast and of low dependency upon the laboratory equipment, and more importantly, it covers multiple abnormal positions of 41 EGFR mutation hotspots within one run.

About 12% of cases by ddPCR and 15% by SuperAMRS were false-negative in this study. The major reason may be the low abundance of cfDNA in plasma. Nonetheless, cancers are heterogeneous, with intra-tumor or inter-tumor showing different genetic profiles. In [Table 2](#t0010){ref-type="table"}, we can see three patients were *EGFR* negative in tumor tissue, but positive in plasma by ddPCR. This may be due to tumor heterogeneity between tumor tissue and plasma. One important advantage of liquid biopsy is potentially fewer heterogeneity issues than tumor tissue biopsy [@bb0065].

Many previous studies demonstrated that there was a significant interaction between cfDNA EGFR mutation status and treatment for PFS [@bb0020], [@bb0025], [@bb0070], [@bb0075]. In accordance with these studies, our study revealed that patients with plasma EGFR mutations had longer PFS as compared to patients without plasma EGFR mutations detected by both ddPCR and SuperARMS, which means both methods predicted well the efficacy of EGFR-TKI by detecting plasma EGFR status.

As we know, although NSCLC patients with EGFR mutation show dramatic responses to EGFR-TKIs, resistance eventually develops in most patients. T790 M mutation is the most common mechanism of EGFR TKI resistance [@bb0080]. Liquid biopsy plays an important role in real-time molecular monitoring of resistance and personalized cancer therapy [@bb0085], [@bb0090]. Both ddPCR and SuperARMS were reported to detect T790M successfully [@bb0060], [@bb0095], [@bb0100]. One main limitation of this study was that we failed to track the dynamic changes of EGFR mutations during treatment. That\'s what we\'re going to do in the future works.

Conclusion {#s0065}
==========

In conclusion, Super-ARMS and ddPCR share the similar accuracy for *EGFR* mutation detection in plasma, both methods predicted well the efficacy of EGFR-TKIs.
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